by sctpn-new | May 13, 2020 | Media Release, Research Trials
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies – CTX001 has received Orphan Drug Designation from the U.S. Food and Drug...
